CD36 and melanoma: The CD36+ SMC state is an attractive therapeutic target in melanoma, as it represents a significant subset of drug-tolerant melanoma cells, accounting for approximately 20%–80% of the population persisting from the early MAPKi-response phase to MRD (7, 19).